Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Total revenue | 10,734 | 361 |
| Operating expenses: | ||
| Cost of product revenue | 200 | — |
| Research and development | 100,081 | 76,240 |
| Selling, general and administrative | 50,831 | 35,526 |
| Total operating expenses | 151,112 | 111,766 |
| Loss from operations | (140,378) | (111,405) |
| Other income (expense): |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's R&D?
- Crinetics Pharmaceuticals (CRNX) reported R&D of $100.08M in Q1 2026.
- How has Crinetics Pharmaceuticals's R&D changed year-over-year?
- Crinetics Pharmaceuticals's R&D increased by 31.3% year-over-year, from $76.24M to $100.08M.
- What is the long-term trend for Crinetics Pharmaceuticals's R&D?
- Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's R&D has grown at a 40.9% compound annual growth rate (CAGR), from $84.26M to $332.06M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Crinetics Pharmaceuticals's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude